https://www.nasdaq.com/press-release/bellicum-regains-compliance-with-nasdaq-continued-listing-requirements-2021-12-13
https://www.nasdaq.com/press-release/bellicum-announces-positive-interim-data-from-phase-1-2-gocar-tr-studies-secures-%2435
https://www.nasdaq.com/press-release/bellicum-reports-third-quarter-2021-financial-results-and-provides-operational-update
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-to-participate-in-the-h.c.-wainwright-23rd-annual-global
https://www.nasdaq.com/press-release/bellicum-and-md-anderson-announce-additional-license-agreement-for-use-of-caspacider
https://www.nasdaq.com/press-release/bellicum-reports-second-quarter-2021-financial-results-and-provides-operational
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1
https://www.nasdaq.com/press-release/bellicum-enters-license-agreement-with-unc-lineberger-and-mass-general-for-use-of
https://www.nasdaq.com/press-release/bellicum-reports-first-quarter-2021-financial-results-and-provides-operational-update
https://www.nasdaq.com/press-release/bellicum-reports-fourth-quarter-2020-financial-results-and-provides-operational
https://www.nasdaq.com/press-release/bellicum-to-report-fourth-quarter-and-full-year-2020-financial-results-and-provide
https://www.nasdaq.com/press-release/bellicum-announces-first-reported-use-of-caspacider-safety-switch-to-mitigate-car-t
https://www.nasdaq.com/press-release/ponce-therapeutics-inc.-commences-first-r-d-program-in-anti-aging-products-for-skin
https://www.nasdaq.com/press-release/bellicum-reports-fda-lifted-clinical-hold-on-bpx-601-phase-1-2-clinical-trial-2021-01
https://www.nasdaq.com/press-release/bellicum-enrolls-first-patient-in-phase-1-2-clinical-trial-for-bpx-603-2020-12-10
https://www.nasdaq.com/press-release/bellicum-reports-clinical-hold-placed-on-bpx-601-phase-1-2-clinical-trial-2020-12-07
https://www.nasdaq.com/press-release/bellicum-reports-third-quarter-2020-financial-results-and-provides-operational-update
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-announces-closing-of-%2425.0-million-underwritten-offering
https://www.nasdaq.com/press-release/bellicum-announces-%2425.0-million-underwritten-offering-priced-at-the-market-2020-10
https://www.nasdaq.com/press-release/bellicum-announces-interim-bpx-601-data-and-corporate-restructuring-2020-10-29
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-09-30
https://www.nasdaq.com/press-release/bellicum-to-participate-in-two-upcoming-virtual-conferences-2020-09-28
https://www.nasdaq.com/press-release/bellicum-to-participate-in-two-upcoming-virtual-investor-conferences-2020-09-02
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-08-31
https://www.nasdaq.com/press-release/bellicum-reports-second-quarter-2020-financial-results-and-provides-operational
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-07-31
https://www.nasdaq.com/press-release/bellicum-to-report-second-quarter-2020-financial-results-and-provide-corporate-update
https://www.nasdaq.com/press-release/bellicum-receives-fda-ind-clearance-to-initiate-a-phase-1-2-clinical-trial-for-bpx
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-05-29
https://www.nasdaq.com/press-release/bellicum-announces-publication-of-data-for-gocar-nktm-cell-program-2020-05-27
https://www.nasdaq.com/press-release/bellicum-to-participate-in-two-upcoming-virtual-investor-conferences-2020-05-27
https://www.nasdaq.com/press-release/bellicum-reports-first-quarter-2020-financial-results-and-provides-operational-update
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-04-30
https://www.nasdaq.com/press-release/bellicum-completes-sale-of-houston-facility-2020-04-15
https://www.nasdaq.com/press-release/bellicum-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/bellicum-to-report-fourth-quarter-and-full-year-2019-financial-results-and-provide
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-02-28
https://www.nasdaq.com/press-release/bellicum-announces-reverse-stock-split-2020-02-05
https://www.nasdaq.com/press-release/bellicum-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-01-31
https://www.nasdaq.com/press-release/bellicum-presents-new-translational-data-for-bpx-601-at-asco-gi-cancers-symposium
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-enters-into-asset-purchase-and-master-services-agreements
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-to-present-new-translational-data-for-bpx-601-at-asco-2020
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-licenses-its-caspacider-safety-switch-to-md-anderson-2019-12
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-presents-encouraging-preclinical-data-for-gocar-nk-cell
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-announces-presentation-on-car-nk-cell-program-at-sitc-2019
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-to-report-third-quarter-2019-financial-results-and-provide
https://www.nasdaq.com/press-release/bellicum-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-0
